

Contents of *The American Journal of Psychiatry*

March 1995

Volume 152

Editorial

Mapping brain activity associated with emotion. *Robert G. Robinson* 327

Images in Neuroscience

Cortex, V: prefrontal leukotomy. *Essay by Daniel R. Weinberger, Terry E. Goldberg and Carol A. Tamminga* 330

Special Article

The glutamatergic basis of human alcoholism. *Guochuan Tsai, David R. Gastfriend and Joseph T. Coyle* 332

Regular Articles

Brain activity during transient sadness and happiness in healthy women. *Mark S. George, Terence A. Ketter, Priti I. Parekh, Barry Horwitz, Peter Herscovitch and Robert M. Post* 341

Health care costs associated with depressive and anxiety disorders in primary care. *Gregory Simon, Johan Ormel, Michael VonKorff and William Barlow* 352

Disproportionate suicidality in patients with comorbid major depression and alcoholism. *Jack R. Cornelius, Ihsan M. Salloum, Juan Mezzich, Marie D. Cornelius, Horacio Fabrega, Jr., Joan G. Ehler, Richard F. Ulrich, Michael E. Thase and J. John Mann* 358

Alcoholism in manic-depressive (bipolar) illness: familial illness, course of illness, and the primary-secondary distinction. *George Winokur, William Coryell, Hagop S. Akiskal, Jack D. Maser, Martin B. Keller, Jean Endicott and Timothy Mueller* 365

Major depression in a community sample of African Americans. *Diane R. Brown, Feroz Ahmed, Lawrence E. Gary and Norweeta G. Milburn* 373

Course and outcome in bipolar affective disorder: a longitudinal follow-up study. *Joseph F. Goldberg, Martin Harrow and Linda S. Grossman* 379

Long-term stability of polarity distinctions in the affective disorders. *William Coryell, Jean Endicott, Jack D. Maser, Martin B. Keller, Andrew C. Leon and Hagop S. Akiskal* 385

Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. *Henry R. Kranzler, Joseph A. Burleson, Patricia Korner, Frances K. Del Boca, Michael J. Bohn, Joseph Brown and Neil Liebowitz* 391

Mood, major depression, and fluoxetine response in cigarette smokers. *Gregory W. Dalack, Alexander H. Glassman, Sarah Rivelli, Lirio Covey and Fay Stetner* 398

Early versus late partial sleep deprivation in patients with premenstrual dysphoric disorder and normal comparison subjects. *Barbara L. Parry, Heidi Cover, Nasim Mostofi, Betina LeVeau, Patricia A. Sependa, Anna Resnick and J. Christian Gillin* 404

Blood dyscrasias with carbamazepine and valproate: a pharmaco-epidemiological study of 2228 patients at risk. *Mauricio Tohen, Jose Castillo, Ross J. Baldessarini, Carlos Zarate, Jr. and Judith C. Kando* 413

Low serum cholesterol level and attempted suicide. *Julia A. Golier, Peter M. Marzuk, Andrew C. Leon, Cindy Weiner and Kenneth Tardiff* 419

Age at onset and familial risk in Alzheimer's disease. *Ge Li, Jeremy M. Silverman, Christopher J. Smith, Michele L. Zaccario, James Schmeidler, Richard C. Mohs and Kenneth L. Davis* 424

High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. *Joseph Biederman, Stephen V. Faraone, Eric Mick, Thomas Spencer, Timothy Wilens, Kathleen Kiely, Jessica Guite, J. Stuart Ablon, Ellen Reed and Rebecca Warburton* 431

Images in Psychiatry

Lauretta Bender, MD, 1899-1987. *Essay by Stella Chess* 436

Brief Reports

Exclusion of the 5-HT_{1A} serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior. *Peter M. Brett, David Curtis, Mary M. Robertson and Hugh M. D. Gurling* 437

Family accommodation in obsessive-compulsive disorder. *Lisa Calvocoressi, Barbara Lewis, Mary Harris, Sally J. Trufan, Wayne K. Goodman, Christopher J. McDougle and Lawrence H. Price* 441

Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. *Perry F. Renshaw, Deborah A. Yurgelun-Todd, Mauricio Tohen, Staci Gruber and Bruce M. Cohen* 444

Quantitative magnetic resonance imaging of the brain in late-life schizophrenia. *Jody Corey-Bloom, Terry Jernigan, Sarah Archibald, M. Jackuelyn Harris and Dilip V. Jeste* 447

Schizophrenia following in utero exposure to the 1957 influenza epidemics in Japan. *Hiroshi Kunugi, Shinichiro Nanko, Noriyoshi Takei, Kaoru Saito, Naoki Hayashi and Hajime Kazamatsuri* 450

Schizophrenia and smoking: an epidemiological survey in a State Hospital. *Jose de Leon, Mahmood Davdand, Carla Canuso, Aruby Odom White, Joseph K. Stanilla and George M. Simpson* 453

Substance abuse and family relationships of persons with severe mental illness. *Lisa Dixon, Scot McNary and Anthony Lehman* 456

Adjustment disorder as an admission diagnosis. *William M. Greenberg, David N. Rosenfeld and Eddy A. Ortega* 459

College Seminars Series

College Seminars is a series of textbooks covering the breadth of psychiatry. As well as helping junior doctors during their training years, *College Seminars* will make a contribution to the continuing medical education of established clinicians.

Seminars In Psychiatric Genetics

By P. McGuffin, M.J. Owen, M.C. O'Donovan, A. Thapar & I.I. Gottesman

Comprehensive coverage of what is known of the genetics of psychiatric disorders, and an introduction to the relevant quantitative and molecular genetic methods.

£10.00, 240pp, 1994, ISBN 902241 65 6

Seminars in Basic Neurosciences

Edited by Gethin Morgan & Stuart Butler

This book will appeal to anyone needing to update their knowledge of the neurological aspects of anatomy, physiology, pharmacology, psychology, pathology, endocrinology and radiology.

£15.00, 336pp, 1993, ISBN 0902241 61 3

Seminars in Psychology and the Social Sciences

Edited by Digby Tantam & Max Birchwood

In some instances the links between clinical practice and the most recent theories considered in this book have yet to be made. However, over the next decade these are likely to dominate the research and service agenda, such as ethnicity as a determinant of health care, connectionist models of mental functioning, and the effects of sex and gender on mental health. For the trainee as well as for the clinician looking for new paradigms in the social sciences, the book will prove an essential source.

£17.50, 358pp, 1994, ISBN 0 902241 62 1

Seminars in Child and Adolescent Psychiatry

Edited by Dora Black & David Cottrell

From assessment to outcome, from normal development to unusual syndromes, from theoretical perspectives to treatment, the reader will find this a clear, concise, and invaluable overview of the field.

£15.00, 298pp, 1993, ISBN 0902241 55 9

Seminars in Alcohol and Drug Misuse

Edited by Jonathan Chick & Roch Cantwell

A clear review of the aetiology, epidemiology, treatment and prevention of dependence on and misuse of alcohol and illicit and prescribed drugs is presented. With a balance of theory, recent research and practical clinical guidelines, the book covers specific and common problems in mental health as well as in general medicine.


£13.50, 246pp, 1994, ISBN 0 902241 70 2

Titles in preparation


■ Psychopharmacology ■ Adult Psychiatric Disorders ■ Learning Disorders and Disabilities ■ Practical Forensic Psychiatry

The books in this series, and other Gaskell publications, are available from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. 0171 235 2351)





*Depressed and anxious, but there's no
need for daytime sedation.*



Treat them with Prozac.

50-70% of patients with depression also have associated anxiety,¹ but today you can treat them just as effectively without daytime sedation.

Prozac lifts depression and associated anxiety as effectively as tricyclics^{2,4} while offering patients a natural nights sleep followed by a sedation-free day.

For today's response to depression, rely on Prozac, the World's No. 1 prescribed brand antidepressant.⁵

Once a day

PROZAC
fluoxetine

*The World's No.1 prescribed
brand name in depression*

'PROZAC' (FLUOXETINE HYDROCHLORIDE) ABBREVIATED PRESCRIBING INFORMATION
Presentation Capsules containing 20mg fluoxetine, as the hydrochloride. Liquid containing 20mg fluoxetine, as the hydrochloride, per 5ml syrup. **Uses** *Depression:* Treatment of the symptoms of depressive illness. *Obsessive-compulsive disorder. Bulimia nervosa:* For the reduction of binge-eating and purging activity. **Dosage and Administration** (For full information, see data sheet.) For oral administration to adults only. *Depression - adults and the elderly:* A dose of 20mg/day is recommended. *Obsessive-compulsive disorder:* 20mg/day to 60mg/day. A dose of 20mg/day is recommended as the initial dose. *Bulimia - adults and the elderly:* A dose of 60mg/day is recommended. Because of the long elimination half-lives of the parent drug (1-3 days after acute administration; may be prolonged to 4-6 days after chronic administration) and its major metabolite (average 9.3 days), active drug substance will persist in the body for several weeks after dosing is stopped. The capsule and liquid dosage forms are bioequivalent. **Children:** Not recommended. **Patients with renal and/or hepatic dysfunction:** See 'Contra-indications' and 'Precautions' sections. **Contra-indications** Hypersensitivity to fluoxetine. Prozac should not be administered to patients with severe renal failure (GFR <10ml/min). **Usage in nursing mothers:** Prozac should not be prescribed to nursing mothers. **Monoamine oxidase inhibitors:** At least 14 days should elapse between discontinuation of an MAOI and initiation of treatment with Prozac. At least five weeks should elapse between discontinuation of Prozac and initiation of therapy with an MAOI. Serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability and mental status changes that include extreme agitation, progressing to delirium and coma) have been reported with concomitant use or when fluoxetine had been recently discontinued and an MAOI started. Some cases presented with features resembling neuroleptic malignant syndrome. **Warnings** *Rash and allergic reactions:* Angioneurotic oedema, urticaria and other allergic reactions have been reported. Upon appearance of rash, or of other allergic phenomena for which an alternative aetiology cannot be identified, Prozac should be discontinued. **Pregnancy:** Use of Prozac should be avoided unless there is no safer alternative. **Precautions** Prozac should be discontinued in any patient who develops seizures. Prozac should be avoided in patients with unstable epilepsy; patients with controlled epilepsy should be carefully monitored. There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment. A lower dose of Prozac, eg, alternate day dosing, is recommended in patients with significant hepatic dysfunction or mild to moderate renal failure (GFR 10-50ml/min). Caution is advisable when Prozac is used in patients with acute cardiac disease. Prozac may cause weight loss which may be undesirable in underweight depressed patients. In diabetics, fluoxetine may alter glycaemic control. There have been reports of abnormal bleeding in several patients, but causal relationship to fluoxetine and clinical importance are unclear. **Drug interactions:** Increased (with lithium toxicity) or decreased lithium levels have been

reported. Lithium levels should be monitored. Because fluoxetine's metabolism involves the hepatic cytochrome P450IID6 isoenzyme system, concomitant therapy with other drugs also metabolised by this system, and which have a narrow therapeutic index (eg, carbamazepine, tricyclic antidepressants), should be initiated at or adjusted to the low end of their dose range. Greater than 2-fold increases of previously stable plasma levels of cyclic antidepressants have been observed when Prozac has been administered in combination. Agitation, restlessness and gastro-intestinal symptoms have been reported in a small number of patients receiving fluoxetine in combination with tryptophan. Patients on stable phenytoin doses have developed elevated plasma concentrations and clinical phenytoin toxicity after starting fluoxetine. **For further information, see data sheet.** **Adverse Effects** Asthenia, fever, nausea, diarrhoea, dry mouth, appetite loss, dyspepsia, vomiting, headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, fatigue, decreased libido, seizures, hypomania or mania, dyskinesia, movement disorders, neuroleptic malignant syndrome-like events, pharyngitis, dyspnoea, pulmonary events (including inflammatory processes and/or fibrosis), rash, urticaria, vasculitis, serum sickness, anaphylactoid reactions, hair loss, excessive sweating, sexual dysfunction. The following have been reported in association with fluoxetine but no causal relationship has been established: aplastic anaemia, cerebral vascular accident, confusion, ecchymoses, eosinophilic pneumonia, gastro-intestinal haemorrhage, hyperprolactinaemia, immune-related haemolytic anaemia, pancreatitis, pancytopenia, suicidal ideation, thrombocytopenia, thrombocytopenic purpura, vaginal bleeding after drug withdrawal and violent behaviour. Hyponatremia (including serum sodium below 110mmol/l) has been rarely reported. This appears to be reversible upon discontinuation. **Overdosage** On the evidence available, fluoxetine has a wide margin of safety in overdose. Since introduction, reports of death, attributed to overdosage of fluoxetine alone, have been extremely rare. One patient who reportedly took 3000mg of fluoxetine experienced 2 grand mal seizures that remitted spontaneously. **Legal Category** POM **Product Licence Numbers** 0006/0195, 0006/0272. **Basic NHS Cost** £20.77 per pack of 30 capsules. £67.85 per pack of 98 capsules. £19.39 per 70ml bottle. **Date of Preparation or Last Review:** Oct. 1994. **Full Prescribing Information is Available From** Dista Products Limited, Dextra Court, Chapel Hill, Basingstoke, Hampshire RG21 2SY Telephone: Basingstoke (0256) 52011. 'PROZAC' is a Dista trade mark. **References:** 1. Kaplan H.L., Sadock B.J. Pocket Handbook of Clinical Psychiatry, 1990. 2. Harris, et al. Data on file, Dista Products Ltd. 3. Judd F, J.A.M.A., S.E.A., 1991; (Dec. Suppl.): 31-33. 4. Stokes P.E., Clin Therap., 1993; 15(2): 216-243. 5. Data on file, Dista Products Ltd. 6. Fairweather D.B., et al. Human Psychopharmacol., 1993; 8: 41-47.

Pz 638 prepared January 1995

